The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage
Open accessAbstract
PURPOSE: To determine whether celecoxib inhibits VEGF secretion from ARPE-19 cells and to investigate further the safety and effectiveness of periocular celecoxib-poly (lactide-co-glycolide; PLGA) microparticles in inhibiting elevations in retinal PGE(2), VEGF, and blood-tissue barrier leakage at the end of 60 days in a streptozotocin diabetic rat model. METHODS: VEGF mRNA and protein expression in ARPE-19 cells was evaluated in the presence of 0 to 10 microM celecoxib, and cytotoxicity of celecoxib on ARPE-19 and RF6A cells was evaluated over a 0- to 100-microM concentration range. Celecoxib-PLGA microparticles were prepared by a modified solvent evaporation technique, sterilized by 25 kGy of gamma-irradiation, and characterized for size, zeta potential, drug loading, and in vitro release. Normal and streptozotocin-diabetic male Sprague-Dawley rats were divided into five groups: normal, diabetic, diabetic+placebo, normal+celecoxib, and diabetic+celecoxib. Phosphate-buffered saline (PBS) containing celecoxib-PLGA microparticles, placebo PLGA microparticles, or plain PBS in one eye was injected into the posterior subconjunctival (periocular) space in rats under anesthesia. Sixty days after administration, the animals were killed, and retinal PGE2 secretion, VEGF protein, and blood-retinal barrier leakage were estimated. Blood cell counts, blood chemistry and histology were used to assess the safety of the microparticulate system. RESULTS: Celecoxib (up to 25 microM) did not cause significant cytotoxicity in ARPE-19 or RF6A cells. Nanomolar concentrations of celecoxib reduced VEGF mRNA and VEGF protein secretion. Celecoxib-PLGA microparticles (diameter: 1140 +/- 15 nm), containing 14.93% +/- 0.21% of celecoxib sustained in vitro drug release and in vivo drug levels in the retina for 60 days. Diabetes elevated PGE2 secretion, VEGF protein, the vitreous-plasma protein ratio, and blood-retinal barrier leakage by 3-, 1.7-, 3.1-, and 2.7-fold, and celecoxib-PLGA microparticles significantly reduced these elevations by 40%, 50%, 40%, and 50%, respectively. Neither the placebo-treated eyes nor the contralateral eyes in celecoxib-PLGA microparticle-treated rats showed significant effects. Celecoxib-PLGA or placebo-PLGA particles had no effect on the body weight or blood sugar level of rats. The celecoxib-PLGA microparticles did not cause any changes in blood cell counts or chemistry and caused no histopathological damage to the retina or periocular tissues. CONCLUSIONS: Nanomolar concentrations of celecoxib can inhibit VEGF mRNA and protein expression from ARPE-19 cells. Periocular celecoxib microparticles are useful sustained drug delivery systems for inhibiting diabetes-induced elevations in PGE2, VEGF, and blood-retinal barrier leakage. The periocular celecoxib-PLGA microparticles are safe and do not cause any damage to the retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Periocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257
Self-citation
Cited by
Role of Inflammation in Diabetic Retinopathy
Rübsam, A., Parikh, S., & Fort, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040942 · Cited by 750
Nonsteroidal Anti-inflammatory Drugs in Ophthalmology
Kim, S. J., Flach, A. J., & Jampol, L. M. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.07.005 · Cited by 383
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
Immunological mechanisms in the pathogenesis of diabetic retinopathy
Adamis, A. P., & Berman, A. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0111-x · Cited by 322
Recent Advances in Ophthalmic Drug Delivery
Kompella, U. B., Kadam, R. S., & Lee, V. H. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.40 · Cited by 285
Self-citation
Metadata
- Authors
- Amrite, A. C., Ayalasomayajula, S. P., Cheruvu, N. P. S., & Kompella, U. B.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2006-03-01
- Volume
- 47
- Issue
- 3
- Pages
- 1149
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2047661114
- Cited by
- 162
- References
- 1
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage. https://app.cochat.ai/papers/10.1167/iovs.05-0531
- The paper
- Amrite, A. C., Ayalasomayajula, S. P., Cheruvu, N. P. S., & Kompella, U. B. (2006). Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.05-0531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.